PRED FORTE SUMMARY
PRED FORTE® (prednisolone acetate ophthalmic suspension, USP) 1% is a topical anti-inflammatory agent for ophthalmic use.
PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Published Studies Related to Pred Forte (Prednisolone Ophthalmic)
A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. [2011.10]
PURPOSE: To compare the effects of 2 corticosteroids on corneal thickness and visual acuity after cataract surgery. DESIGN: Multicenter, randomized, contralateral-eye, double-masked trial... CONCLUSIONS: In this high-dose pulsed-therapy regimen, difluprednate reduced inflammation more effectively than prednisolone acetate, resulting in more rapid return of vision. Difluprednate was superior at protecting the cornea and reducing macular thickening after cataract surgery. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. [2011.01]
PURPOSE: To compare the efficacy of intravitreal injection of clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis... CONCLUSIONS: Intravitreal injection of clindamycin and dexamethasone may be an acceptable alternative to the classic treatment in ocular toxoplasmosis. It may offer the patient more convenience, a safer systemic side effect profile, greater availability, and fewer follow-up visits and hematologic evaluations. Copyright (c) 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Methylprednisolone applied directly to the round window reduces dizziness after cochlear implantation: a randomized clinical trial. 
This prospective, double-blind controlled, randomized clinical trial of 43 adults showed that topical methylprednisolone applied to the round window during cochlear implantation was effective in protecting inner ear function. Postoperative vestibular disturbance was significantly lower in the steroid group (5%) than the control group (29%)...
Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. [2010.10]
PURPOSE: The aim of this study was to evaluate the efficacy and safety of difluprednate ophthalmic solution 0.05% (Durezol; Alcon Laboratories, Fort Worth, TX) compared with prednisolone acetate ophthalmic suspension 1% (Pred Forte; Allergan, Inc., Irvine, CA) for endogenous anterior uveitis... CONCLUSIONS: Difluprednate administered QID is at least as effective as prednisolone administered 8x/day in resolving the inflammation and pain associated with endogenous anterior uveitis. Difluprednate provides effective treatment for anterior uveitis and requires less frequent dosing than prednisolone acetate. Clinical trial registration: Trial NCT00501579 was registered at the National Institutes of Health Registry in July 2007 ( http://clinicaltrials.gov/ct2/show/NCT00501579?term=sirion&rank=4 ).
Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. [2010.05]
PURPOSE: To compare orbital floor triamcinolone acetonide and oral prednisolone in cataract surgery in patients with chronic non-infectious uveitis with regard to visual outcome, postoperative inflammation and macular edema... CONCLUSIONS: A single intraoperative orbital floor injection of triamcinolone acetonide is as effective on postoperative inflammation, macular edema, and visual outcome as a 4-week course of postoperative oral prednisolone in cataract surgery with IOL implantation in uveitis patients.
Clinical Trials Related to Pred Forte (Prednisolone Ophthalmic)
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach [Recruiting]
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with
polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose
glucocorticoids ( 5 mg/day of prednisone) as compared to stopping glucocorticoid treatment
entirely (0 mg/day of prednisone)on rates of disease relapse/disease flares.
This study is a novel approach to conducting a randomized clinical trial in the community
setting. This study is being conducted in parallel with a similar study at established
vasculitis institutions. This study will have a patient centric approach to research in
that subjects will be recruited online and through social media and vasculitis support
networks. Participants will be consented online and will receive care through their regular
treating physician so no travel or additional doctor visits are required. Study participants
will consent to the study and complete online questionnaires about their prednisone dose and
about how they are feeling.
Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant [Terminated]
The purpose of the study was to determine if rapid discontinuation of corticosteroids (also
known as prednisone withdrawal) and maintenance immunosuppression with Prograf (tacrolimus)
and CellCept (mycophenolate mofetil) while using Thymoglobulin (Rabbit antithymocyte
globulin) will give similar safety and efficacy results compared to continuation of
corticosteroids (also known as prednisone maintenance) and standard maintenance
immunosuppression with Prograf (tacrolimus), CellCept (mycophenolate mofetil) while using
Thymoglobulin (Rabbit antithymocyte globulin).
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone [Recruiting]
Tuberculosis (TB) is the most common opportunistic infection amongst HIV-infected patients
starting antiretroviral therapy (ART) in developing countries and thus the most frequent
form of immune reconstitution inflammatory syndrome (IRIS). Paradoxical TB-IRIS occurs in 8-
43% of patients starting ART while on TB treatment and results in morbidity,
hospitalisation, consumes health care resources and TB-IRIS may be fatal. We have previously
demonstrated in a clinical trial that prednisone reduces morbidity when used for treatment
of paradoxical TB-IRIS. This trial is a double-blind placebo-controlled trial of
prophylactic prednisone (40mg/day for 2 weeks followed by 20mg/day for 2 weeks, started on
the same day as ART) in patients with TB who are identified as being at high risk for
paradoxical TB-IRIS (starting ART within 30 days of initiating TB treatment and CD4 <
100/μL). The trial will enroll 240 participants, randomised 1: 1 (prednisone: placebo). The
primary endpoint is development of paradoxical TB-IRIS, defined using international
consensus case definitions. Secondary endpoints include time to IRIS event, severity of
IRIS, quality of life assessment, mortality and corticosteroids adverse events. The trial is
powered to determine a reduction in TB-IRIS events.
Dose-comparison Study of Prednisone in Heart Failure [Completed]
The purpose of this study is to examine the efficacy of three doses of prednisone, a
glucocorticoid, in treatment of patients with symptomatic heart failure.
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach [Recruiting]
This study is a multi-center randomized controlled trial to evaluate the effects of using
low-dose prednisone as compared to stopping prednisone treatment entirely. Participants will
be randomized 1: 1 to taper their prednisone dose down to 5 mg/day or to 0 mg/day for the
duration of the study (approximately six months) or until a study endpoint.
Reports of Suspected Pred Forte (Prednisolone Ophthalmic) Side Effects
Intraocular Pressure Increased (14),
Drug Ineffective (11),
Vision Blurred (9),
Eye Oedema (7),
Visual Acuity Reduced (6),
Corneal Opacity (5),
Condition Aggravated (4),
Eye Irritation (3), more >>
Page last updated: 2011-12-09